Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality
By
William Morgenlander,
Stephanie Henson,
Daniel Monaco,
Athena Chen,
Kirsten Littlefield,
Evan M Bloch,
Eric Fujimura,
Ingo Ruczinski,
Andrew R Crowley,
Harini Natarajan,
Savannah E Butler,
Joshua A Weiner,
Mamie Z. Li,
Tania S. Bonny,
Sarah E. Benner,
Ashwin Balagopal,
David Sullivan,
Shmuel Shoham,
Thomas C. Quinn,
Susan Eshleman,
Arturo Casadevall,
Andrew D Redd,
Oliver Laeyendecker,
Margaret E. Ackerman,
Andrew Pekosz,
Stephen J Elledge,
Matthew Robinson,
Aaron AR Tobian,
H. Benjamin Larman
Posted 18 Dec 2020
medRxiv DOI: 10.1101/2020.12.16.20248294
COVID-19 convalescent plasma, particularly plasma with high-titer SARS-CoV-2 (CoV2) antibodies, has been successfully used for treatment of COVID-19. The functionality of convalescent plasma varies greatly, but the association of antibody epitope specificities with plasma functionality remains uncharacterized. We assessed antibody functionality and reactivities to peptides across the CoV2 and the four endemic human coronavirus (HCoV) genomes in 126 COVID-19 convalescent plasma donations. We found strong correlation between plasma functionality and polyclonal antibody targeting of CoV2 spike protein peptides. Antibody reactivity to many HCoV spike peptides also displayed strong correlation with plasma functionality, including pan-coronavirus cross-reactive epitopes located in a conserved region of the fusion peptide. After accounting for antibody cross-reactivity, we identified an association between greater alphacoronavirus NL63 antibody responses and development of highly neutralizing antibodies to SARS-CoV-2. We also found that plasma preferentially reactive to the CoV2 receptor binding domain (RBD), versus the betacoronavirus HKU1 RBD, had higher neutralizing titer. Finally, we developed a two-peptide serosignature that identifies plasma donations with high anti-S titer but that suffer from low neutralizing activity. These results suggest that analysis of coronavirus antibody fine specificities may be useful for selecting therapeutic plasma with desired functionalities.
Download data
- Downloaded 572 times
- Download rankings, all-time:
- Site-wide: 41,814
- In infectious diseases: 2,291
- Year to date:
- Site-wide: 3,707
- Since beginning of last month:
- Site-wide: 3,707
Altmetric data
Downloads over time
Distribution of downloads per paper, site-wide
PanLingua
News
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!